Synthesis and structure of [(η(6)-p-cymene)Ru(2-anthracen-9-ylmethylene-N-ethylhydrazinecarbothioamide)Cl]Cl; biological evaluation, topoisomerase II inhibition and reaction with DNA and human serum albumin

Metallomics. 2011 May 1;3(5):491-502. doi: 10.1039/c1mt00003a. Epub 2011 Feb 23.

Abstract

We have synthesized and evaluated the biological properties of a compound of the type [η(6)-p-cymene)Ru(EtATSC)Cl]Cl (1) where EtATSC = 2-anthracen-9-ylmethylene-N-ethylhydrazinecarbothioamide, a thiosemicarbazone. The complex has been characterized by elemental analysis, spectroscopically (NMR, UV-Vis, and IR) and structurally by XRD. The in vitro anticancer activity of 1 has been evaluated against two human colon cancer cell lines. The IC(50) value for activity against HCT-116 was 224 ± 7 μM and 205 ± 5 μM against the Caco-2 cell line. The proficiency of 1 as an antibacterial agent was also evaluated against six bacterial strains. The minimum inhibitory concentration for Bacillus cereus was determined to be 5 μM and for Enterococcus faecalis it was 20 μM. At the maximum concentration tested the complex showed no activity against the Gram-negative strains. The complex binds strongly to human serum albumin with a binding constant of 1.37 ± 0.02 M(-1) at 308 K on a single binding site. It is also a strong binder to DNA with an apparent binding constant of 2.82 × 10(5) M(-1) at 308 K. 1 shows very good activity as a catalytic inhibitor of human topoisomerase II at concentrations as low as 20 μM.

MeSH terms

  • Anti-Bacterial Agents / chemical synthesis
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Bacillus cereus / drug effects
  • Bacillus cereus / growth & development
  • Biocatalysis / drug effects
  • Caco-2 Cells
  • Cell Survival / drug effects
  • Coordination Complexes / chemical synthesis
  • Coordination Complexes / chemistry*
  • Coordination Complexes / pharmacology
  • Crystallography, X-Ray
  • Cymenes
  • DNA / chemistry*
  • DNA Topoisomerases, Type II / metabolism
  • Enterococcus faecalis / drug effects
  • Enterococcus faecalis / growth & development
  • HCT116 Cells
  • Humans
  • Inhibitory Concentration 50
  • Kinetics
  • Molecular Structure
  • Organometallic Compounds / chemical synthesis
  • Organometallic Compounds / chemistry*
  • Organometallic Compounds / pharmacology
  • Ruthenium / chemistry*
  • Serum Albumin / chemistry*
  • Thiosemicarbazones / chemistry*
  • Time Factors
  • Topoisomerase II Inhibitors / chemical synthesis
  • Topoisomerase II Inhibitors / chemistry
  • Topoisomerase II Inhibitors / pharmacology

Substances

  • (eta6-p-cymene)ruthenium(2-anthracen-9-ylmethylene-N-ethylhydrazinecarbothioamide)
  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Coordination Complexes
  • Cymenes
  • Organometallic Compounds
  • Serum Albumin
  • Thiosemicarbazones
  • Topoisomerase II Inhibitors
  • Ruthenium
  • DNA
  • DNA Topoisomerases, Type II